MedTrace Logo

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

NCT00608595 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-03-05

No results posted yet for this study

Summary

RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how rectal cancer will respond to treatment with celecoxib.

PURPOSE: This clinical trial is studying how well celecoxib works in treating patients with early-stage rectal cancer.

Conditions

Interventions

DRUG

celecoxib

Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.

GENETIC

gene expression analysis

not noted

GENETIC

protein expression analysis

Not noted

OTHER

immunohistochemistry staining method

not noted

OTHER

laboratory biomarker analysis

not noted

OTHER

mass spectrometry

PROCEDURE

biopsy

At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.

PROCEDURE

neoadjuvant therapy

not noted

PROCEDURE

therapeutic conventional surgery

not noted

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • A. Bapsi Chakravarthy, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2004-05-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608595 on ClinicalTrials.gov